Navigation Links
Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month Formulation in Advanced Prostate Cancer
Date:2/12/2008

- Presentation of Efficacy and Safety Phase III Results -

LAUSANNE, Switzerland, Feb. 12 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, presented today at the 9th International Symposium on GnRH in Berlin, Germany, the results of a phase III study with its new 6-month formulation of Decapeptyl(R)/Trelstar(R) (triptorelin), a luteinizing hormone releasing hormone (LHRH) agonist for the treatment of advanced prostate cancer. These results show similar efficacy and safety to the already marketed 1- and 3-month formulations.

This multicenter, open, non-comparative, phase III study on the efficacy and safety of two consecutive injections of triptorelin 6-month formulation in 120 patients with advanced prostate cancer, showed that 97.5% of patients achieved castrate levels of serum testosterone 28 days after the first injection and that 93% of the patients maintained serum testosterone levels below castrate level (defined as < or equal to 1.735 nmol/L or 50 ng/dL) from week 8 to 48. These efficacy results are similar to those obtained previously with repeated administrations of the 1- and 3-month formulations of triptorelin. Furthermore the adverse event profile of the new 6-month formulation of triptorelin is fully comparable to that observed with the 1- and 3-month formulations.

"Our 1- and 3-month formulations of Decapeptyl(R) and Trelstar(R) are used worldwide in the treatment of prostate cancer. However they require one injection every 4 or 12 weeks respectively. The 6-month formulation will improve patient compliance and increase convenience and comfort with the need of only one intramuscular injection every 24 weeks," said Kamel Besseghir, CEO of Debiopharm S.A.

About Decapeptyl(R)/Trelstar(R)

Triptorelin was licensed-in from Tulane University in 1982. Debiopharm developed and submitted a 1- and 3-month sustained release formulation of triptorelin embonate in Europe and the United States. The product is now marketed worldwide for the treatment of advanced prostate cancer, endometriosis, precocious puberty, in-vitro fertilisation programs, and uterine fibroids. Licensees include Ipsen, Watson, Ferring, Tecnofarma, Ache, Rowfarma and Sidus. Current licensee sales are of US $300M.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.6 billion in 2006.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com.

Debiopharm S.A. Contacts Additional Media Contacts

Herve Porchet In London

VP, Medical Affairs Maitland

Tel.: +41 (0)21 321 01 11 Brian Hudspith

Fax: +41 (0)21 321 01 69 Tel.: +44 (0)20 7379 5151

hporchet@debiopharm.com bhudspith@maitland.co.uk

In New York

Russo Partners, LLC

Wendy Lau

Tel.: +1 212-845-4272

Fax: +1 212-845-4260

wendy.lau@russopartnersllc.com


'/>"/>
SOURCE Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. AGI Dermatics Clinical Data Indicate Bicyclic Monoterpene Diols Suppress MMP1 and Stimulate Collagen Through TNF-a Signaling
2. Genetic Immunity Presents Clinical Data on DermaVir Patch Immune Therapy at 15th Annual Conference on Retroviruses and Opportunistic Infections
3. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
4. Independent Clinical Results Confirm Up to a 7-Centimeter Reduction in Body Circumference Using UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring System
5. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
6. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
7. IDX899 Demonstrates Rapid and Profound Inhibition of HIV Replication in a Phase I/II Clinical Trial in Treatment-Naive HIV-Infected Patients
8. Rapid Growth of Asia-Pacific Clinical Trials Market Focus of New CenterWatch Report
9. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
10. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
11. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... India , December 7, 2016 According to ... (Services, Software), Delivery Mode, Product Type (Integrated, Standalone), Model (Knowledge-Based), Type (Therapeutic, ... MarketsandMarkets, The CDSS Market is expected to reach USD 1,519.2 Million by ... Continue Reading ... ...
(Date:12/7/2016)... , Dec. 7,2016  Based on ... delivery industry, Frost & Sullivan recognizes Nemaura ... & Sullivan Award for Enabling Technology Leadership. ... the loopholes in traditional drug delivery technologies, ... liquid microneedle-based drug delivery technologies, Memspatch and ...
(Date:12/7/2016)... Inc. (NASDAQ: IONS ), the leader in antisense therapeutics, ... BMO Capital Markets Prescriptions for Success Healthcare Conference on Wednesday, December ... A live webcast of the presentation will be available on the ... be available within 48 hours and will be archived for a ... , , ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... , ... “The Road To Restoration”: an informative and enlightening book for ... week showing of hands. “The Road To Restoration” is the creation of published author, ... the brass ring that you could reach out for, and grab, on the old ...
(Date:12/7/2016)... ... ... “Walking With God: Inspirational Lessons from My Life's Journey”: a sometimes serious, ... God's direction in their lives. “Walking With God: Inspirational Lessons from My Life's Journey” ... , Sanford says, “I enjoy sharing the true stories in my book ...
(Date:12/7/2016)... ... (PRWEB) December 07, 2016 , ... Angioma Alliance ( ... cavernous angiomas, was awarded a grant from the Julian Grace Foundation to increase ... has more people with cavernous angioma than anywhere in the world. Most share ...
(Date:12/7/2016)... ... 07, 2016 , ... Dr. Greg Leyer, the Chief Scientific ... Washington DC workshop on November 2nd. The conference was an opportunity for both ... supplement regulations. , Dr. Leyer spoke about two main topics at the ...
(Date:12/7/2016)... ... 2016 , ... "Hacking into my medical record wouldn’t be hard for my ... begins "Margaret in Berlin," Book Twelve in the Margaret of Greenwich ® Young ... These novels narrate the lives of a poor teenager and her wealthy friends in ...
Breaking Medicine News(10 mins):